NASONEX NASAL SPRAY

Country: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

MOMETASONE FUROATE 50 MCG/DOSE

Disponibbli minn:

MERCK SHARP & DOHME ISRAEL LTD

Kodiċi ATC:

D07AC13

Għamla farmaċewtika:

SOLUTION

Rotta amministrattiva:

NASAL

Manifatturat minn:

SCHERING-PLOUGH LAB.NV BELGIUM

Grupp terapewtiku:

MOMETASONE

Indikazzjonijiet terapewtiċi:

In adults and children 3 years of age and older to treat the symptoms of seasonal or perennial rhinitis. In patients 12 years old and above who have a history of moderate to severe symptoms of seasonal allergic rhinitis prophylactic treatment with Nasonex Aqueous Nasal Spary is recommended 2- 4 weeks prior to the anticipated start of the pollen season.

Data ta 'l-awtorizzazzjoni:

2013-03-01